Colorectal Cancer Clinical Trials

Virginia Mason Franciscan Health is relentlessly devoted to providing exceptional health care—which is why we conduct clinical studies to improve the way we diagnose, treat and prevent disease. 

Our cancer experts collaborate with Benaroya Research Institute and the Center for Digestive Health to offer colon cancer studies. Our trials include the use of chemotherapy, radiation and targeted therapies, as well quality of life and symptom management trials.

Virginia Mason Franciscan Health has a long-standing partnership with Benaroya Research Institute, which is a national leader in immunology and immune tolerance research. Our research program offers clinical trials for Crohn’s disease and ulcerative colitis in conjunction with the Center for Digestive Health and Benaroya Research Institute.

Learn more about our current colon cancer clinical trials:

PACES: Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III

Short course Radiation and TASOX (TAS102 plus Oxaliplatin) chemotherapy in operable rectal cancer, a phase II trial

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study

A Pilot Protocol Evaluating Safety of the Medtronic Pump and Codman Catheter for the Delivery of Hepatic Arterial Infusion (HA I) Chemotherapy in patients with advanced Colorectal Carcinoma or Cholangiocarcinoma

Protocol for the Comparison of Surgery and Medicine on the Impact of Diverticulitis (COSMID) Trial

Clinical Validation of An Optimized Multi-Target Stool DNA (mt-sDNA 2.0) Test, for Colorectal Cancer Screening “BLUE-C”

BLOOD COLLECTION SUB-STUDY OF EXACT SCIENCES PROTOCOL 2019-01: “CLINICAL VALIDATION OF AN OPTIMIZED MULTI-TARGET STOOL DNA (mt-sDNA 2.0) TEST, FOR COLORECTAL CANCER SCREENING BLUE-C”

Learn more about our current IBD clinical trials for Crohn’s disease and ulcerative colitis.

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohn's Disease

A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicenter Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants with Crohn's Disease Who Completed the Studies M14-431 or M14-433

A Phase 3, Multicenter, Randomized, Efficacy Assessor-Blinded Study of Risankizumab Compared to Ustekinumab for the Treatment of Adult Subjects with Moderate to Severe Crohn’s Disease Who Have Failed Anti-TNF Therapy

Risankizumab in Participants with Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065

A Multicenter, Randomized, Double-Blind, Placebo-Controlled   Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis

To talk with a clinical research coordinator about clinical research trials related to colorectal cancer, call the Cancer Clinical Research Unit hotline at 206-287-6270.

For all non-cancer related clinical research trials, contact the Center for Digestive Health research team at 206-341-1021.